|
Delayed
Japan Exchange
07:19:50 08/06/2026 am IST
|
5-day change
|
1st Jan Change
|
|
3,818.00 JPY
|
+1.14%
|
 |
+0.16%
|
-18.15%
|
|
20/05 |
Eisai Co., Ltd. Provides Earnings Guidance for the Fiscal Year 2026 (April 2026 to March 2027)
|
CI
| |
15/05 |
Eisai Co., Ltd. Announces Dividend for the Fiscal Year Ended March 31, 2026, Payable on June 1, 2026; Provides Dividend Guidance for Second Quarter- End and Fiscal Year Ending March 31, 2027
|
CI
| |
15/05 |
Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2027
|
CI
| |
15/05 |
Eisai Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2026
|
CI
| |
08/05 |
Eisai Co., Ltd. and Biogen Inc. Update on Fda Priority Review of Leqembi Iqlik (Lecanemab-Irmb) Subcutaneous Injection as A Starting Dose for Early Alzheimer's Disease
|
CI
| |
30/04 |
Eisai Posts 88 Billion Yen Leqembi Revenue For Fiscal 2025
|
MT
| |
30/03 |
Final dividend
|
FA
| |
27/03 |
Eisai Co., Ltd. and MSD K.K. Submit Application for Lenvima in Combination with Welireg for Renal Cell Carcinoma in Japan
|
CI
| |
23/03 |
Eisai Present New Data on Long-Term Real-World Treatment with Lecanemab
|
CI
| |
20/03 |
Eisai Co Ltd And Biogen Inc Announce Real-World Long-Term Treatment Persistence With Leqembi
|
CI
| |
20/03 |
Eisai Co., Ltd. And Biogen Inc. Present Real-World Data On Leqembi (Lecanemab-Irmb) Treatment Persistence In The United States
|
CI
| |
19/03 |
Eisai to discontinue administration of anticancer agent EZH2 inhibitor Tazverik tablets 200 mg manufactured and marketed in Japan
|
RE
| |
17/03 |
Eisai Co., Ltd. Announces Establishment of Eisai Global Capability Centre Within Eisai Knowledge Centre, India, in Visakhapatnam, Andhra Pradesh, India
|
CI
| |
16/02 |
Eisai Co., Ltd. Announces Orphan Drug Designation for E2086, a Novel Selective Orexin 2 Receptor Agonist for Narcolepsy
|
CI
| |
09/02 |
Eisai's Nine-Month Profit Falls 8.1%
|
MT
| |
09/02 |
Eisai Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2025
|
CI
| |
06/02 |
Eisai Co Ltd - revenue of Leqembi (preliminary basis)
|
RE
| |
27/01 |
Eisai Submits Marketing Authorisation Variation to EMA for Intraous Maintenance Dosing Every Four Weeks with Leqembi®?
|
CI
| |
26/01 |
Eisai Announces Leqembi® Iqlik? (Lecanemab-Irmb) Supplemental Biologics License Application Regarding Subcutaneous Starting Dose Granted Priority Review by the US FDA
|
CI
| |
26/01 |
Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepts Eisai Co., Ltd.'s Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Priority Review
|
CI
| |
06/01 |
Eisai Announces Biologics License Application for the Subcutaneous Formulation of Leqembi for Treatment of Early Alzheimer's Disease
|
CI
| |
04/12 |
Eisai Presents the Latest Findings on Time Savings with Continued Treatment with Leqembi
|
CI
| |
04/12 |
Eisai Co., Ltd. and Biogen Inc. Present New Data
|
CI
| |
02/12 |
Eisai Co., Ltd. Presents New Data on Anti-Tau Antibody Etalanetug At CTAD 2025
|
CI
| |
28/11 |
Eisai Announces New Drug Application for Subcutaneous Formulation of Leqembi Subcutaneous Formulation Ofleqembi Subcutaneous Form Formulation of Leqemab
|
CI
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
